Ascentage Pharma raises $126m in first biotech IPO of 2025
The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood cancer.
Ascentage prices first biotech IPO of 2025, raising $126M
The China-based cancer drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.
Ascentage prices first US IPO of the year
Ascentage Pharma Group Corp. Ltd. has priced the first IPO of the year in the U.S. The offering of 7.32 million shares has the Suzhou, China, and Rockville, Md.-based company looking for gross proceeds of about $126.
Ascentage Pharma’s US Shares Climb After $126 Million IPO
Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s US trading debut, after pricing its $126.4 million initial public offering at a discount to its Asian stock.
Takeda-backed Ascentage Pharma aims to raise $126 million in US IPO
Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.
Takeda-backed Ascentage Pharma prices $126M U.S. IPO
Ascentage Pharma Group (AAPG) (AAPGV) (OTCPK:ASPHF), which is backed by Takeda (NYSE:TAK), has priced a $126M U.S. initial public offering. The China-based drug developer priced 7.33M shares at $17.25 per share,
Hosted on MSN2d
HSG Laser’s China IPO Failure: Behind the 1.32 Billion RMB Fundraising Setback
Guangdong Hongshi Laser Technology Co., Ltd. (HSG Laser) has failed to complete its initial public offering (IPO), marking a ...
U.S. IPO Weekly Recap: Venture Global Prices A Pared-Down IPO As More Sizable Deals Join The Pipeline
Seven IPOs and one SPAC priced this past week, as more sizable issuers filed to go public in the US. Read more here.
The Edge Singapore1d
ESR China REIT successfully lists on Shanghai Stock Exchange, raising over RMB 2.1 bil
This is ESR’s first REIT in China, and comprises three stabilised logistics facilities that have an average occupancy of 90%.
Chinese Soda Maker Dayao Is Said to Consider $500 Million HK IPO
Chinese soda maker Dayao is gearing up for a Hong Kong initial public offering as early as the second half of 2025, people ...
Forbes India8d
China's steep barriers for IPOs come with serious economic costs
Within days of its $4.4 billion IPO on the New York Stock Exchange last June, the Chinese ride-hailing giant Didi Global got ...
Skift3d
Tourism's Rebound, Trump's Orders and Hopper's IPO Move
Today’s episode discusses the recovery of global tourism, Hopper’s possible IPO, and the impact of Trump’s orders on tourism.
Food Processing2d
Smithfield Foods’ IPO: 34.8 Million Shares at $23-27 Per Share
The country’s top pork processor reveals the size and price range of its long-rumored separation from China’s WH Group, but a ...
TechCrunch on MSN11d
Xiaohongshu (RedNote), China’s answer to Instagram, hits No. 1 on the App Store as TikTok faces US shutdown
On the heels of TikTok's looming shutdown on January 19 over its ownership in the U.S. (unless the Supreme Court intervenes), ...